title: Nuclear factor-kappa B inhibitors; a patent review (2006-2010).
abstract: BACKGROUND
  Nuclear factor (NF)-κB, as transcription factor, is linked to the expression of various genes and plays an essential role in immune and inflammatory responses. Abnormal NF-κB signaling results in human diseases, such as immune disorders, inflammation and various cancers. Therefore, regulation of NF-κB may treat or improve the symptoms in human disorders.
  
  
  METHODS
  This review provides information on recent NF-κB inhibitor-related patents from 2006 to 2010. The patents are explained and categorized by mechanism. The reader will gain an understanding of NF-κB function and the structure and biological activity of recently developed NF-κB inhibitors that may be new drug candidates.
  
  
  CONCLUSIONS
  NF-κB plays an essential role in the human body and thus regulation of NF-κB is very important for the treatment of diseases. Furthermore, patented compounds and peptides are available as lead compounds in drug development studies.
authors.affiliation: Chungbuk National University, College of Pharmacy, Cheongju 361-763, Republic of Korea.
authors.forename: Jae-Hwan
authors.initials: JH
authors.lastname: Kwak
authors.forename: Jae-Kyung
authors.initials: JK
authors.lastname: Jung
authors.forename: Heesoon
authors.initials: H
authors.lastname: Lee
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010330:Patents as Topic; D015398:Signal Transduction / Q000187:drug effects; D013329:Structure-Activity Relationship
chemical_list: D000893:Anti-Inflammatory Agents; D016328:NF-kappa B